Aurora Cannabis Receives Production License for Aurora Eau Facility and Oils Production License for MedReleaf's Bradford Facility

Aurora Cannabis Receives Production License for Aurora Eau Facility and Oils Production License for MedReleaf's Bradford Facility

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced the Company has obtained a Health Canada production permit for its Aurora Eau facility in Lachute, Quebec. The Company now has seven centers licensed for production, with a production capacity in excess of 160,000 kg per annum. Aurora has added facilities under development, bringing the total funded capacity to over 500,000 kg per annum.

Furthermore, Aurora, through its wholly-owned subsidiary MedReleaf Corp. (“MedReleaf”), has obtained its oils production license for its Bradford facility (“MedReleaf Bradford”), which at full capacity is a 28,000 kg per annum cultivation facility. MedReleaf Bradford comes with a high-volume CO2 extraction facility, which will considerably increase oils production, and is in the process of stockpiling significant amounts of derivative products in anticipation of receipt of its sales permit.

Differentiated Cultivation Facility

Aurora Eau, located in Lachute, Quebec (CNW Group/Aurora Cannabis Inc.)

Aurora Eau, a foot facility with a production capacity of 4,500 kg each year, represents the next evolution in Aurora’s indoor-grow facilities and was. Aurora Eau has been built to permit flexibility in all important production parameters to optimally accommodate the provider’s present”exotic” cultivars as well as new strains not yet launched and new genetics under development, intended for both the medical and adult consumer use markets.

Aurora Eau is built on 46 acres of prime agricultural land, which Aurora has the right to buy for $136,000 for expansion purposes. The weighted footprint of the Company would expand in Quebec, providing additional capacity to support supply and future product development.

Towards obtaining EU GMP certification, as part of the Company’s commitment to further supply chain diversification and the Aurora Standard the Company will continue to progress, as with its other facilities. Up to now, Aurora has two EU GMP cultivation facilities in Canada, as well as an EU GMP certified facility located in Germany, run by its subsidiary Aurora Europe GmbH, for the import, release, and distribution of cannabis.

Cultivation Commenced in Eau

Cultivation mature plants using a custom built transporter, designed by Aurora’s wholly owned subsidiary BC and has commenced at Aurora Eau, after receipt of a mix of clones Northern Lights. The new transporter allows Aurora to transfer high-volumes of Mothers and Clones cost-effectively, enabling the population of facilities that are new. After the move, Aurora Eau is currently in production.

External View: BC Northern Lights Developed Clone Transporter (CNW Group/Aurora Cannabis Inc.)

Internal View: BC Northern Lights Developed Clone Transporter (CNW Group/Aurora Cannabis Inc.)

Management Commentary

“We are proud of the achievements at Aurora Eau, and with seven production licenses we are exceptionally well positioned to continue executing on our early mover advantage, in both the Canadian and the international markets,” stated Terry Booth, CEO of Aurora. “With large-scale production scaling up at Aurora Sky, we’ve got the capacity to dedicate production from Aurora Eau to niche markets, thereby growing our brand recognition and enhancing our margin profile. Our new oils production permit at Bradfordfurther increases our capacity to produce increased margin oils, and drive growth.”

Choice and RSU Grant

The options have a term of five years and vest annually over 36 months. Additionally, stock units were awarded to a director of the Company, of which, 8,859 vest December 31, 2018 and 119,668 vest annually over 36 months.

Headquartered in Edmonton, Alberta, Canada with capacity that is funded in excess of 570,000 kg annually and sales and operations in 14 countries across five continents, Aurora is one of cannabis businesses that are leading and the world’s largest. Aurora is horizontally diversified and integrated across each sector of the value chain, from facility design and engineering to cannabis breeding and genetics research, hemp and cannabis production, derivatives product development, home farming, retail and wholesale distribution.

Highly differentiated by its peers, Aurora has created a uniquely innovative, consistent and effective production strategy, based on purpose-built centers which incorporate leading-edge technologies across all processes, defined by extensive automation and customization, leading to the gigantic scale production of high quality product at ultra-low expenses. Intended to be scalable and replicable globally, these production facilities are designed to make cannabis of scale, with higher quality, industry-leading yields, and ultra-low per g production expenses. Each of Aurora’s facilities is built to meet European Union (EU) GMP standards, and its first production facility, as well as the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Europe, have attained this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which thus far includes 10 companies acquired — MedReleaf, CanvasRx, Peloton Pharmaceutical, Pedanios, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, and Anandia — Aurora is distinguished by its reputation as a partner of choice and employer of choice in the World cannabis industry, having invested in and established strategic partnerships with a range of top innovators, such as: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Capcium Inc. (private), and Alcanna Inc. (TSX: CLIQ).

Aurora’s Common Shares trade on the TSX under the symbol”ACB”, and are a constituent of the S&P/TSX Composite Index.

To Learn More about Aurora, please see our investor website,, Twitter, Facebook or Instagram

CEO, terry Booth
Aurora Cannabis Inc..

Forward-looking statements are frequently characterized by words such as”plan”,”continue”,”expect”,”project”,”intend”,”believe”,”expect”,”estimate”,”may”,”will”,”potential”,”proposed” and other similar words, or statements that certain events or conditions”may” or”will” occur. These statements are only predictions. Numerous assumptions were used in drawing the conclusions or making the projections found throughout this news release in the forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to many different risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content with multimedia:

Released at Fri, 07 Sep 2018 17:03:31 +0000

Posted in: News

Comments are closed.